Abbott Laboratories (ABT) on Monday announced that Health Canada has approved its dissolvable stent, the Esprit BTK Everolimus Eluting Resorbable Scaffold System.
The device is used to treat people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). It keeps arteries open and delivers the drug everolimus to support healing before the stent fully dissolves.
More than 800,000 Canadians are living with Peripheral Artery Disease (PAD). CLTI is a severe form of PAD in which arteries become clogged with plaque, blocking blood flow and oxygen to the lower leg and foot. People with CLTI often experience severe pain and non-healing open wounds.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.